Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.2
Journals
Microorganisms
Special Issues
State-of-the-Art Antimicrobial Agents and Resistance Research in Germany
Due to scheduled maintenance work on our servers, there may be short service disruptions on this website between 11:00 and 12:00 CEST on March 28th.
share announcement

State-of-the-Art Antimicrobial Agents and Resistance Research in Germany

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 472

Special Issue Editor

Dr. Catalina-Suzana Stingu

E-Mail Website
Guest Editor
Institute for Medical Microbiology and Virology, Section Medicam Microbiology, University of Leipzig Medical Center, Leipzig, Germany
Interests: oral microbiology; oral biofilm; anaerobes; antimicrobial resistance; dental infections
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The emergence of antimicrobial resistance is an urgent global health problem that requires urgent attention to slow the spread of resistant pathogens. The United States Centers for Disease Control and Prevention (CDC) has emphasized clinician-driven antimicrobial stewardship approaches, including the reporting and proper documentation of antimicrobial usage and resistance.

This Special Issue is designed to offer a comprehensive overview of the latest advancements in antimicrobial agents and resistance within Germany.

We, therefore, invite German researchers from related fields to submit papers that highlight recent developments in this area. Contributions may include original research articles about bacterial and fungal resistance but also about antimicrobial therapy, including non-antibiotic approaches such as antimicrobial peptides or bacteriophages, as well as comprehensive reviews. We also encourage the invitation of relevant experts and colleagues to contribute, ensuring a diverse and cutting-edge collection of work. This Special Issue aims to showcase the innovative research being conducted in Germany and provide a platform for further advancements in the field of antimicrobial agents and resistance.

Dr. Catalina-Suzana Stingu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobials
  • antimicrobial resistance (AMR)
  • antibiotics
  • antibiotic-resistant bacteria (ARBs)
  • antibiotic-resistant genes (ARGs)
  • antimicrobial peptides
  • bacteriophage therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 703 KB  
Article
In Vitro Activity of Mupirocin Against Methicillin-Resistant Staphylococcus aureus (MRSA) in Two Periods of Time (2016 and 2021–2022) in a Large University Hospital in Germany
by Arved Carl Christian Westphal, Mandy Vogel and Catalina Suzana Stingu
Microorganisms 2026, 14(3), 650; https://doi.org/10.3390/microorganisms14030650 - 13 Mar 2026
Viewed by 268
Abstract
Colonization with methicillin-resistant Staphylococcus aureus (MRSA) increases the risk of adverse health outcomes, and it is estimated that 10–30% of carriers subsequently develop infection. Mupirocin is currently widely used as a topical decolonization measure against nasal methicillin-resistant S. aureus (MRSA) carriers. The present [...] Read more.
Colonization with methicillin-resistant Staphylococcus aureus (MRSA) increases the risk of adverse health outcomes, and it is estimated that 10–30% of carriers subsequently develop infection. Mupirocin is currently widely used as a topical decolonization measure against nasal methicillin-resistant S. aureus (MRSA) carriers. The present study was carried out in order to determine the prevalence rate of high-level (HLMuR) and low-level (LLMuR) mupirocin-resistant MRSA strains among patients treated at our hospital over two periods of time (2016 and 2021–2022) and to observe possible changes in MRSA susceptibilities against mupirocin after a six-year period of use. This is a retrospective study carried out on MRSA isolated from various clinical specimens from inpatients. A total of 474 MRSA isolates found in nasal, nasopharyngeal, throat, wound, urine and prostheses swabs were examined. All S. aureus isolates were identified using MALDI-TOF mass spectrometry scores ≥ 2 and confirmed as MRSA using the cefoxitin (30 µg) disc diffusion method. Mupirocin-resistant MRSA was detected by the Epsilometer test (E-test). All the resistant strains were tested for Panton-Valentine-Leucocidin (PVL) toxin by PCR. Out of 481 strains in our database, 474 pure non-duplicate MRSA isolates were included in our study. Mupirocin resistance was found in 15 (3.2%) MRSA strains by E-test, whereby three (0.6%) isolates were HLMuR and 12 (2.5%) isolates were LLMuR. The prevalence of mupirocin-resistant MRSA was similar in 2016 (10.6%) and 2021 (12.9%) and decreased to 6.5% in 2022. Even though the decrease in the proportion of resistant isolates from 2021 to 2022 did not reach statistical significance (p = 0.103), the mean resistance level among resistant isolates decreased significantly over the study period (p ≤ 0.001), dropping from 94.3 µg/ml in 2016 to 46.4 µg/ml in 2021 with a further decrease to 0.7 µg/ml in 2022. Although the mupirocin resistance decreased in 2022 compared with 2016, continuous monitoring of mupirocin resistance development in MRSA and surveillance of excessive use is of utmost importance in order to rule out possible failure of mupirocin decolonization treatment with subsequent increased mortality due to infections, prolonged hospital stays and more difficult treatment requirements at an early stage. Full article
(This article belongs to the Special Issue State-of-the-Art Antimicrobial Agents and Resistance Research in Germany)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop